Download DNB 2017 Dec MED ONCO MED ONCO PAPER I Question Paper

FirstRanker.com

DECEMBER 2017
MEDICAL ONCOLOGY

--- Content provided by​ FirstRanker.com ---

PAPER - I
Time : 3 hours MED.ONCO./D/17/17/1 Max. Marks :100

Important instructions:
Attempt all questions in order.
Each question carries 10 marks.

--- Content provided by‍ FirstRanker.com ---

Read the question carefully and answer to the point neatly and legibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer all the parts of a single question together.
Start the answer to a question on a fresh page or leave adequate space between two answers.

--- Content provided by⁠ FirstRanker.com ---

Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. a. Enumerate breakthrough hallmarks of cancer (3+3+4)
   b. List of tumours and indications where anti-angiogenic approach has shown positive results
   c. List three anti-angiogenic agents in clinical practice and their side effects.

--- Content provided by⁠ FirstRanker.com ---

2. a. What is minimal residual disease (MRD) with respect to acute lymphoblastic leukemia? (3+5+2)
   b. Enumerate methods of MRD detection and their advantages and disadvantages:
   c. How is MRD detection different in B-ALL Vs T-ALL?
3. a. Enumerate the steps in performing Polymerase Chain Reaction (PCR). (5+2+3)
   b. Name two methods of performing real time PCR.
   

   --- Content provided by‍ FirstRanker.com ---

   c. Mention three applications of PCR in oncology.
4. a. Mechanism of action of cisplatin. (2+4+4)
   b. Mechanism and markers of platinum resistance in various cancers.
   c. Pharmacogenomics of cisplatin induced ototoxicity.
5. a. Principles of extra corporeal radiotherapy (ECRT) (4+3+3)
   

   --- Content provided by‌ FirstRanker.com ---

   b. Mention specific condition where ECRT may be used.
   c. What are the problems associated with ECRT?
6. a. What are chimeric Antigen Receptor (CAR)-T cells? (4+4+2)
   b. How are CAR-T cells different from Blinatumomab with respect to use in acute lymphoblastic leukemia (ALL)?
   c. Beside ALL, name two other conditions where CAR-T cells are being used.

--- Content provided by⁠ FirstRanker.com ---

7. a. What is Hedgehog pathway? (4+2+4)
   b. Name the cancers where this pathway is relevant.
   c. Utility of Hedgehog pathway inhibitors.
8. a. Mechanism of action and method of administration of trabectedin. (4+3+3)
   b. Side effects of trabectedin
   

   --- Content provided by‍ FirstRanker.com ---

   c. Therapeutic uses of trabectedin
9. a. What are end points for a Trial pertaining to newer therapies in palliative care setting and why? (5+5)
   b. What is Basket Trial? Explain with example.
10. a. Explain next generation and whole genome sequencing. (5+5)
    b. Explain with an example how the above may be useful in oncologic therapeutics.

--- Content provided by‌ FirstRanker.com ---

POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.

FirstRanker.com